Nevro Corp.

Equities

NVRO

US64157F1030

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:01 2024-04-26 pm EDT			5-day change	1st Jan Change
11.32 ^USD	-2.58%		-6.21%	-47.40%

Apr. 15	RBC Lowers Price Target on Nevro to $16 From $18, Keeps Sector Perform Rating	MT
Apr. 11	Mizuho Adjusts Price Target on Nevro to $16 From $20, Maintains Neutral Rating	MT

Nevro Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 02, 2022 at 04:51 pm EDT

Nevro Corp. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 100.47 million compared to USD 93.21 million a year ago. Net income was USD 81.51 million compared to net loss of USD 50.08 million a year ago. Basic earnings per share from continuing operations was USD 2.3 compared to basic loss per share from continuing operations of USD 1.44 a year ago. Diluted earnings per share from continuing operations was USD 2.22 compared to diluted loss per share from continuing operations of USD 1.44 a year ago.
For the nine months, sales was USD 292.52 million compared to USD 284.15 million a year ago. Net income was USD 22.19 million compared to net loss of USD 101.23 million a year ago. Basic earnings per share from continuing operations was USD 0.63 compared to basic loss per share from continuing operations of USD 2.91 a year ago. Diluted earnings per share from continuing operations was USD 0.63 compared to diluted loss per share from continuing operations of USD 2.91 a year ago.

Latest news about Nevro Corp.

RBC Lowers Price Target on Nevro to $16 From $18, Keeps Sector Perform Rating	Apr. 15	MT
Mizuho Adjusts Price Target on Nevro to $16 From $20, Maintains Neutral Rating	Apr. 11	MT
Citigroup Cuts Price Target on Nevro to $16 From $18, Maintains Neutral Rating	Apr. 03	MT
Nevro 2024 Sales Expected Slightly Below Estimates, RBC Says	Feb. 22	MT
Wells Fargo Adjusts Price Target on Nevro to $17 From $20, Maintains Equal-Weight Rating	Feb. 22	MT
Baird Cuts Price Target on Nevro to $19 From $23, Maintains Neutral Rating	Feb. 22	MT
Oppenheimer Downgrades Nevro to Perform From Outperform, Removes $35 Price Target	Feb. 22	MT
RBC Lowers Price Target on Nevro to $18 From $20, Keeps Sector Perform Rating	Feb. 22	MT
Earnings Flash (NVRO) NEVRO Posts Q4 Revenue $116.2M, vs. Street Est of $116M	Feb. 21	MT
Engaged Capital Enters into Agreement with Nevro Corp	Feb. 21	CI
Transcript : Nevro Corp., Q4 2023 Earnings Call, Feb 21, 2024	Feb. 21
Nevro Corp. Appoints Kirt P. Karros to Board of Directors and Audit Committee of the Board	Feb. 21	CI
Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2024	Feb. 21	CI
Nevro Corp. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 21	CI
RBC Downgrades Nevro to Sector Perform From Outperform, Cuts Price Target to $20 From $23	Jan. 12	MT
Transcript : Nevro Corp. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 08:15 AM	Jan. 11
Sector Update: Health Care Stocks Mixed in Afternoon Trading	Jan. 09	MT
Nevro to Cut 5% of Workforce in Restructuring, Says Preliminary Q4 Revenue Rose 2%	Jan. 09	MT
Truist Securities Adjusts Price Target on Nevro to $23 From $22, Maintains Hold Rating	Dec. 22	MT
Canaccord Genuity Downgrades Nevro to Hold From Buy, $23 Price Target	Dec. 21	MT
Nevro Corp. Enters into Certain Credit Agreement	Dec. 01	CI
Nevro Acquires Vyrsa Technologies, Closes Term Loan Credit Facility; Shares Rise After Hours	Nov. 30	MT
Nevro Corp. acquired Vyrsa Technologies for $75 million.	Nov. 29	CI
Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain	Nov. 20	CI
Truist Securities Adjusts Price Target on Nevro to $17 From $18.50, Keeps Hold Rating	Nov. 03	MT

Chart Nevro Corp.

Duration

Period

More charts

Company Profile

Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-06 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Nevro Corp.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

11.32 USD

Average target price

17.73 USD

Spread / Average Target

+56.65%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
NEVRO CORP.	-47.40%	426M
ABBOTT LABORATORIES	-2.31%	185B
MEDTRONIC PLC	-3.20%	105B
BECTON, DICKINSON AND COMPANY	-5.04%	66.59B
DEXCOM, INC.	+0.20%	54.66B
CENCORA, INC.	+17.29%	47.78B
HOYA CORPORATION	+4.06%	41.26B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.95B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.37B
TERUMO CORPORATION	+12.96%	24.8B

Other Medical Equipment, Supplies & Distribution